KZIA Kazia Therapeutics Limited
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibi…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Bank of New York Mellon Corporation (BNY) Lost A Depositary Mandate Bank of New York Mellon Corporation (NYSE:BNY) has been replaced as depositary for Kazia Therapeutics Limited’s American Depositary Receipt program. Kazia Therapeutics has appointed JPMorgan Chase Bank, N.A. as the new depositary for its ADRs, according to the company’s latest update. The shift away from Bank of New York Mellon Corporation in Kazia’s ADR program highlights a change in a visible client mandate for BNY’s capital markets services. The replacement of Bank of New York Mellon... | ||
 Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence? Kazia Therapeutics Limited (NASDAQ:KZIA) has materially strengthened its financing position, but the clinical case for expanding paxalisib into HR-positive, HER2-negative metastatic breast cancer remains at the preclinical stage. Paxalisib is an investigational, brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway. On August 31, Kazia Therapeutics Limited (NASDAQ:KZIA) closed a registered public offering that Kazia Therapeutics Limited (NASDAQ:KZIA) […] | ||
Kazia Therapeutics Reports Preclinical Tumor Reduction in Colorectal Cancer Study Kazia Therapeutics (KZIA) said Tuesday that data showed its paxalisib therapy significantly reduced | ||
 Kazia closes oversubscribed offering to fund paxalisib’s clinical development Paxalisib is being studied in various cancers and has received several regulatory designations from the FDA. | ||
Kazia Therapeutics Proposes Tranched Public Offering Kazia Therapeutics (KZIA) said late Thursday it has commenced a tranched registered public offering | ||